文献速递脊柱关节炎其他结缔组织病

银屑病关节炎或银屑病患者启动生物制剂后主要心血管不良事件或充血性心力衰竭的短期风险:随机对照试验的荟萃分析

Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials.
PubMed 文献 · RMD Open · 2019-01-24

结果显示,与安慰剂相比,生物制剂未显著增加MACE或CHF发生率;抗IL12/23组观察到10例MACE(1150患者年) vs 安慰剂组1例(652患者年),风险差0.01(-0.00至0.02)事件/患者年,无统计学意义。

要点

  • 生物制剂短期不显著增加MACE或CHF风险。
  • 抗IL12/23组MACE数值较高但无统计学意义。
  • 抗IL23组未观察到类似趋势。

核心结论

  • 银屑病关节炎或银屑病患者启动生物制剂后短期MACE或CHF风险无显著变化。

主要发现

  • 抗TNF、抗IL12/23、抗IL23或抗IL17药物与安慰剂相比MACE发生率无显著差异。
  • 抗IL12/23组MACE为10例(1150患者年),安慰剂组为1例(652患者年),风险差0.01(-0.00至0.02)事件/患者年,无统计学意义。
  • 抗IL23组未观察到MACE趋势。
  • 生物制剂与安慰剂相比CHF发生率无显著差异。

关键数值与推荐

  • MACE风险差0.01(-0.00至0.02)事件/患者年,无统计学意义。

临床怎么用

  • 临床决策时可参考本荟萃分析结果,生物制剂短期不显著增加MACE或CHF风险。

局限性

  • 仅评估短期风险,未涉及长期心血管结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective was to investigate the short-term risk of major adverse cardiovascular events (MACEs) or congestive heart failure (CHF) in patients with psoriatic arthritis (PsA) or psoriasis initiating a biological therapy. METHODS: Screening for the study was carried out using MEDLINE, Cochrane and Embase, from the inception of the database to December 2017. Randomised controlled trials (RCTs) of anti-tumour necrosis factor (TNF), anti-interleukin (IL)12/23, anti-IL23 and anti-IL17 agents for the treatment of PsA or psoriasis were included. Two investigators independently extracted MACEs or CHF data reported during the placebo-controlled phase. The primary outcome measures were the incidence of MACEs or CHF. RESULTS: Of 753 references screened, 62 articles were selected, and 12 articles were added by manual searches. Accordingly 77 RCTs were included in the meta-analysis (MA) (10 174 patient-years (P-Y)). No significant difference was observed in MACE incidences in patients receiving anti-TNF, anti-IL12/23, anti-IL23 or anti-IL17 agents in comparison to the placebo. However, 10 MACEs were observed in the anti-IL12/23 group (1150 P-Y) compared with 1 in the placebo group (652 P-Y), with 0.01 -0.00 to 0.02 event/P-Y risk difference, which is not statistically significant. This trend was not observed in the anti-IL23 group. No significant difference was observed in CHF incidence in patients receiving biological agents in comparison to placebo. CONCLUSION: This MA of 77 RCTs did not reveal any significant change in the short-term risk of MACE or CHF in patients with PsA or psoriasis initiating a biological therapy.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Champs B, Degboé Y, Barnetche T, et al. Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials. RMD Open. 2019. PMID: 30792887. doi:10.1136/rmdopen-2018-000763

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。